How Do We Best Employ Animal Models for Type 1 Diabetes and Multiple Sclerosis?, Volume 1103

by Von Herrath, Matthias; Atkinson, Mark A.; Hafler, David A.; Roep, Bart O.

• ISBN13: 9781573316781
• ISBN10: 1573316784
• Edition: 1st
• Format: Paperback
• Copyright: 2007-05-14
• Publisher: Wiley-Blackwell

Summary

Our understanding of the genetics and pathophysiology of animal models for autoimmune diseases such as type 1 diabetes and multiple sclerosis has increased significantly in the past few years. The central themes of this volume are the necessity for novel and improved models, the optimal use of information from animal models to understand pathogenesis of the human disease, and the rational development of novel immunotherapeutics.This volume is intended to foster discussion on the utility of currently available animal models, to suggest methods for improving upon present models, and to advance translational research in these fields.NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit www.nyas.org/membership/main.asp for more information about becoming a member.

Author Biography

Matthias Von Herrath is the editor of How Do We Best Employ Animal Models for Type 1 Diabetes and Multiple Sclerosis?, Volume 1103, published by Wiley. Mark Atkinson is a medical researcher best known for his contributions to research seeking to predict, prevent, and cure type 1 diabetes. He is the author of over 425 publications and is one of the world's most cited diabetes researchers.

Table of Contents

Introduction

Controversies Surrounding the Use of Animal Models in Type 1 Diabetes and Multiple Sclerosis

Are Insights Gained from NOD Mice Sufficient to Guide Clinical Translation? Another Inconvenient Truth

Building Different Mouse Models for Human MS

Autoimmunity and β Cell Regeneration in Mouse and Human Type 1 Diabetes. The Peace Is Not Enough

Diabetes Research in Jeopardy: The Extinction of Clinical Diabetes Researchers

New Methods of Discovery for Questions of Pathogenesis and Therapy:In Silico

The Virtual NOD Mouse: Applying Predictive Biosimulation to Research in Type 1 Diabetes

Dosing and Timing Effects of Anti-CD40L Therapy: Predictions from a Mathematical Model of Type 1 Diabetes

Autoreactive T Cells in a Partially Humanized Murine Model of T1D

Humanized NOD/LtSz-scid IL2 Receptor Common Gamma Chain Knockout Mice in Diabetes Research

Development of New-Generation HU-PBMC-NOD/SCID Mice to Study Human Islet Alloreactivity

Resistance to the Induction of Mixed Chimerism in Spontaneously Diabetic NOD Mice Depends on the CD40/CD154 Pathway and Donor MHC Disparity

"Humanized" HLA Transgenic NOD Mice to Identify Pancreatic β Cell Autoantigens of Potential Clinical Relevance to Type 1 Diabetes

A New Humanized HLA Transgenic Mouse Model of Multiple Sclerosis Expressing Class II on Mouse CD4 T Cells

The Use of Idd Congenic Mice to Identify Checkpoints of Peripheral Tolerance to Islet Antigen

Refinement of the Iddm4 Diabetes Susceptibility Locus Reveals TCRV β4 as a Candidate Gene

Cytotoxic T Cell -Mediated Diabetes in RIP-CD80 Transgenic Mice: Autoantigen Peptide Sensitivity and Fine Specificity

Coxsackievirus Infections and NOD Mice: Relevant Models of Protection from, and Induction of, Type 1 Diabetes

Establishment of a Model to Examine the Early Events Involved in the Development of Virus-Induced Demyelinating Lesions

Experimental Autoimmune Encephalomyelitis Mediated by CD8 and T Cells

Impaired T Cell Receptor Signaling in Foxp3 and CD4 T Cells

Antigen Presentation in the CNS by Myeloid Dendritic Cells Drives Progression of Relapsing Experimental Autoimmune Encephalomyelitis

Table of Contents provided by Publisher. All Rights Reserved.